Jessica Hedeman, DO
Neurology · Grand Rapids, MINPI 1639310196
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,665 of the $167,047 with a category attached, or 72.8%. 18 manufacturers reported payments, led by MDD US Operations, LLC at 59.6% of the total. 2025 is the largest year on record at $61,272, 5.9 times the $10,303 reported in 2019. Among neurology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $716.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$100K
- Neurocrine Biosciences, Inc.$43K
- Acorda Therapeutics, Inc$16K
- Adamas Pharmaceuticals, Inc.$7K
- Boston Scientific$337
- Kyowa Kirin, Inc.$164
- plus $726 from 12 others
What the payments were for
- Consulting fees$14,8109%
- Speaking & faculty fees$121,66573%
- Travel & lodging$26,82916%
- Food & beverage$3,7412%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 99 | $99,556 |
| Neurocrine Biosciences, Inc. | 68 | $43,057 |
| Acorda Therapeutics, Inc | 19 | $16,074 |
| Adamas Pharmaceuticals, Inc. | 8 | $7,133 |
| Boston Scientific | 8 | $337 |
| Kyowa Kirin, Inc. | 4 | $164 |
| AbbVie | 4 | $141 |
| Teva Pharmaceuticals USA, Inc. | 2 | $121 |
| Abbott | 4 | $92 |
| Acadia Pharmaceuticals Inc | 4 | $79 |
| Medtronic(2 entities) | 3 | $69 |
| Sunovion Pharmaceuticals Inc. | 3 | $64 |
| Avion Pharmaceuticals | 2 | $50 |
| Supernus Pharmaceuticals, Inc. | 1 | $33 |
| GE HealthCare | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Revance Therapeutics, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$167,047 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $279,499 |
| AustedoDeutetrabenazine | 43 | $238,504 |
| GocovriAmantadine Hcl | 68 | $195,918 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $136,032 |
| RytaryCarbidopa/Levodopa | 70 | $122,783 |
| NuplazidPimavanserin Tartrate | 15 | $74,345 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 927 | $68,870 |
| InbrijaLevodopa | 31 | $42,907 |
| NourianzIstradefylline | 11 | $30,336 |
| Entacapone | 120 | $24,718 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 303 | $21,538 |
| AmantadineAmantadine Hcl | 181 | $18,234 |
| Rasagiline Mesylate | 38 | $11,140 |
| Pramipexole ErPramipexole Di-Hcl | 14 | $8,871 |
| Selegiline Hcl | 55 | $6,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $43,057 | $279,49937 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $121 | $238,50443 claims |
| MDD US Operations, LLCGocovri | $99,556 | $195,91868 claims |
| Amneal Pharmaceuticals LLCRytary | $21 | $122,78370 claims |
| Acadia Pharmaceuticals IncNuplazid | $79 | $74,34515 claims |
| Acorda Therapeutics, IncInbrija | $16,074 | $42,90731 claims |
| Kyowa Kirin, Inc.Nourianz | $164 | $30,33611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.
Other neurology in Grand Rapids
- Jared PomeroyGrand Rapids$329K
- Melanie TaylorGrand Rapids$91K
- Nicholas LannenGrand Rapids$58K
- Danette TaylorGrand Rapids$47K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.